FibroGen, Inc. (FGEN)

Oncology Corporate Profile

Stock Performance

19.2100
-0.5700

3 Month Stock History Chart

HQ Location

409 Illinois St.
San Francisco, CA 94158

Company Description

FibroGen is a privately-held biotechnology company focused on the discovery, development, and commercialization of therapeutic agents for treatment of fibrosis, anemia, cancer, and other serious unmet medical needs. FibroGen's FG-3019 fully human monoclonal antibody is in clinical development for treatment of idiopathic pulmonary fibrosis and other proliferative diseases, including pancreatic cancer and liver fibrosis. Roxadustat (FG-4592), FibroGen's small molecule inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylase, is currently in clinical development for the treatment of anemia. FibroGen is also currently pursuing the use of proprietary recombinant human type III collagens in synthetic corneas for treatment of corneal blindness.

Website: http://www.fibrogen.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
FG-3019-069anti-fibrotic antibodyPancreactic adenocarcinomaII

View additional information on product candidates here »

Source: http://www.fibrogen.com

Recent News Headlines

8/21/2017 06:19 am

8/21/2017 06:19 am

8/21/2017 06:19 am

8/21/2017 06:19 am

8/21/2017 06:19 am

8/17/2017 06:18 am

8/17/2017 06:18 am

8/17/2017 06:18 am

8/17/2017 06:18 am

8/17/2017 06:18 am

8/17/2017 12:18 am

8/17/2017 12:18 am

8/17/2017 12:18 am

8/17/2017 12:18 am

8/15/2017 06:18 pm

8/15/2017 06:18 pm

8/15/2017 06:18 pm

8/15/2017 06:18 pm

8/15/2017 06:18 pm

8/14/2017 12:18 pm

8/12/2017 12:20 pm

8/10/2017 06:18 am

8/9/2017 06:18 am

8/8/2017 12:18 pm

8/8/2017 12:18 am